Morè, S.; Offidani, M.; Corvatta, L.; Petrucci, M.T.; Fazio, F. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers2023, 15, 2948.
Morè, S.; Offidani, M.; Corvatta, L.; Petrucci, M.T.; Fazio, F. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers 2023, 15, 2948.
Morè, S.; Offidani, M.; Corvatta, L.; Petrucci, M.T.; Fazio, F. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers2023, 15, 2948.
Morè, S.; Offidani, M.; Corvatta, L.; Petrucci, M.T.; Fazio, F. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers 2023, 15, 2948.
Abstract
Despite the recent approval of novel immunotherapies, as immunomodulatory drug, proteasome inhibitors and anti-CD38 monoclonal antibodies, Multiple Myeloma (MM) remains incurable and the acquisition of triple-refractoriness leads to really dismal outcomes, in even earlier lines of therapy. More recently, innovative therapeutic strategies targeting B cell maturation antigen (BCMA), highly expressed on the plasma cell surface, are drawing different future landscapes in terms of effectiveness and outcomes. Belantamab Mafodotin, a first-in-class anti-BCMA antibody drug conjugates, demonstrated good efficacy and safety profile in triple-refractory patients in the phase 2 DREAMM-2 trial and it was approved for the treatment of MM triple-exposed patients with >4 prior lines of therapy. Here, starting from Belantamab Mafodotin clinical trials also exploring combination studies and different schedules in order to improve its efficacy and toxicity, we focused on real life experiences all over the world, which have confirmed clinical trial data and encourage further Belantamab Mafodotin investigations
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
